Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

WuXi Biologics and WuXi AppTec to Spend $2.8 Billion to Build Separate Singapore Facilities

publication date: Jul 22, 2022

WuXi Biologics and WuXi AppTec announced that each company would invest $1.4 billion over ten years to build R&D and manufacturing facilities in Singapore. The sites will offer CRDMO (Contract Research, Development and Manufacturing Organization) services to each companies’ clients. Over the past few years, both companies have invested heavily to expand their physical presences around the globe while also incorporating new technologies. Their respective CEOs characterized the expansion into Singapore as the next logical step of their continuing growth globally. Although the two companies are separate, both operate under the umbrella of WuXi PharmaTech. More details....

Stock Symbols: (HK; 2269) (SHA: 603259)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China